BRIEF

on Isomorphic Labs

Isomorphic Labs and MSD Announce Strategic Research Partnership

On November 19, 2026, Isomorphic Labs, a company focused on AI-driven drug design, and MSD, known as Merck & Co., Inc. in the USA, revealed a joint research initiative. This collaboration combines Isomorphic's AI capabilities in drug discovery with MSD's vast proprietary data and expertise.

The partnership aims to develop therapeutic small molecule candidates for an important oncology target. Isomorphic will deploy its IsoDDE drug design engine, using select data from MSD. MSD will handle preclinical and clinical activities, alongside manufacturing and commercialization.

Isomorphic will receive an upfront fee and could earn milestone payments and royalties. The firm also has an option to co-fund development activities. Key leaders from both companies expressed excitement about this collaboration, which highlights the synergy of advanced AI and pharmaceutical expertise.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Isomorphic Labs news